No Data
No Data
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
Notable Healthcare Headlines for the Week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in Focus
Nvidia, Nike, Sarepta Therapeutics, Protalix and More Analyst Calls of the Week
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Evercore Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $123
Sarepta Therapeutics (SRPT) Receives a Buy From Evercore ISI